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BACKGROUND: Gestational trophoblastic disease (GTD) is a rare complication of pregnancy, ranging from molar pregnancy to
choriocarcinoma. Patients with persistent disease require treatment with chemotherapy. For the vast majority, prognosis is excellent.
Occasionally, GTD is complicated by hyperthyroidism, which may require treatment. This is thought to occur due to molecular
mimicry between human chorionic gonadotrophin (HCG) and thyroid-stimulating hormone (TSH), and hence cross-reactivity with
the TSH receptor. Hyperthyroidism usually resolves as the GTD is successfully treated and correspondingly HCG levels normalise.
METHODS: This paper reviews cases of GTD treated over a 5-year period at one of the three UK centres and identifies the prevalence
of hyperthyroidism in this population. Four cases with clinical hyperthyroidism are discussed.
RESULTS: On review of the 196 patients with gestational trophoblastic neoplasia treated with chemotherapy in Sheffield since 2005,
14 (7%) had biochemical hyperthyroidism. Of these, four had evidence of clinical hyperthyroidism.
CONCLUSION: Concomitant biochemical thyroid disease in patients with GTD is relatively common, and measurement of thyroid
function in patients with persistent GTD is, therefore, important. The development of hyperthyroidism is largely influenced by the
level of HCG and disease burden, and usually settles with treatment of the persistent GTD. However, rarely the thyroid stimulation
can have potentially life-threatening consequences.
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Gestational trophoblastic disease (GTD) is an uncommon compli-
cation of pregnancy with an incidence in the United Kingdom of
approximately 1.5/1000 births (Bagshawe et al, 1986). Gestational
trophoblastic disease is essentially a family of diseases that
includes complete and partial molar pregnancy, choriocarcinoma
and placental site trophoblastic tumour. Choriocarcinoma is a
malignant form of GTD, occurring in approximately 1 : 70000
pregnancies per year, and may occur after a normal pregnancy
(post-partum choriocarcinoma) (Ober et al, 1971).
In the United Kingdom, all women with molar pregnancies are
registered at one of the three dedicated GTD centres (London,
Sheffield, Dundee) for ongoing monitoring and treatment if
necessary. The centre in Sheffield receives 500–600 registrations
each year. Approximately 6–8% of women subsequently require
treatment, usually chemotherapy, for persistent disease (gesta-
tional trophoblastic neoplasia, GTN). The prognosis is excellent
with a cure rate in excess of 95% (Fisher and Hancock, 1997).
There is well-documented evidence of the association between
high serum human chorionic gonadotrophin (HCG) levels and
suppressed thyroid-stimulating hormone (TSH) in normal preg-
nancy (Braunstein and Hershman, 1976; Glinoer et al, 1990), often
in the context of hyperemesis gravidarum (Goodwin et al, 1992).
Less often, this association is seen in gestational neoplasia and
other germ cell malignancies in which HCG is secreted. Often in
these cases, this is an incidental finding, the free T3 (FT3) and free
T4 (FT4) are within normal limits, and the patient is asympto-
matic. Patients rarely require any treatment, and the thyroid
function tests (TFTs) normalise as the serum HCG falls. The effect
on the thyroid is thought to occur due to molecular mimicry
between HCG subunits and TSH (Fisher and Hancock, 1997). The
potency of HCG for TSH receptors is some 4000 times less than
TSH and hence, extremely high levels of HCG are usually required
for an effect on thyroid function to be seen.
There have been a small number of case reports of GTD
presenting in association with symptomatic hyperthyroidism
(Odell et al, 1963; Morley et al, 1976; Anderson et al, 1979;
Norman et al, 1981; Soutter et al, 1981).
Here, we review TFT results in patients treated at our centre
over the past 5 years, and report on four patients with clinical
hyperthyroidism.
MATERIALS AND METHODS
All chemotherapy prescribed at Weston Park Hospital is done
through Chemocare, an electronic prescribing system. This system
was used to create a database of all patients commencing
chemotherapy for GTN between January 2005 and January 2010.
The diagnoses of the patients treated were confirmed by cross-
referencing with their medical notes and their biochemical
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markers (HCG, TSH, FT3 and FT4) were obtained from our
computerised results recording system.
RESULTS
On review of the 196 patients with GTN treated with chemotherapy
in Sheffield since 2005, 14 (7%) had biochemical hyperthyroidism.
Of these, four had evidence of clinical hyperthyroidism. All
patients had HCG levels of 4100 000 IU l–1. Most patients had
HCG levels between 100 000 and 500 000 IU l–1 at presentation
(Figure 1).
Case 1 was a usually well, 22-year-old female who, following an
uncomplicated pregnancy, presented 24 days after the normal
vaginal term delivery of her third child. The delivery was
complicated by a retained placenta, which required manual
evacuation. She subsequently presented twice to her local hospital
with heavy vaginal bleeding, breathlessness and tachycardia. She
underwent a surgical evacuation of her uterus, although no
specimens were sent for histology. Her serum HCG was found to
be 1.077 106 IU l–1 (normal range o2 IU l– 1). Chest X-ray
showed multiple cannon-ball lesions and a presumed diagnosis
of post-partum choriocarcinoma was made.
On transfer to our centre, she was unwell with haemodynamic
instability, breathlessness, fever and abdominal pain with disten-
sion. Further staging investigations confirmed multiple lung
metastases, and pelvic ultrasound showed an 18 8 8 cm3 intra-
uterine mass. Magnetic resonance imaging (MRI) of the brain was
normal. She was calculated to have a World Health Organisation
(WHO) risk score of 12 (Kohom, 2001) (Table 1) and commenced
on first-line high-risk chemotherapy with intravenous metho-
trexate, alternating with intravenous dactinomycin and etoposide
(IV MAE).
As per our local policy, her thyroid function was measured at
time of presentation. She was found to have hyperthyroidism with
TSH o0.03mIU l–1 (normal range 0.35–4.5mIU l–1), FT3 6.5
pmol l – 1 (normal range 3.5–6.5 pmol l– 1) and FT4 36.3 pmol l – 1
(normal range 10.0–19.8 pmol l – 1). Thyroid auto-antibodies were
negative. She was commenced on carbimazole 40mg daily (OD)
and propranolol 40mg three times daily prior to commencement
of chemotherapy.
She responded quickly to chemotherapy with rapid falls in
serum HCG (Table 2; Figure 2). She was clinically and
biochemically euthyroid by commencement of her third cycle of
chemotherapy. Her carbimazole and propranalol were steadily
reduced and subsequently stopped. Her HCG level has now
normalised, she has completed chemotherapy and is clinically well,
with clinical and biochemical euthyroidism off all treatment.
Case 2 was a 21-year-old woman who presented to her local
hospital with abdominal pain and haemodynamic instability, while
taking the oral contraceptive pill. A pregnancy test was positive,
but ultrasound of the pelvis revealed an empty uterus. She
underwent a right salpingetcomy for a presumed ruptured ectopic
pregnancy. She was commenced on depo-contraceptive immedi-
ately following her surgery. Two months following her ectopic
pregnancy, she re-presented with abdominal pain and a raised
serum HCG of 140 000 IU l–1. A pelvic ultrasound showed an
empty uterus and a complex mass arising in the right side of the
pelvis. A pelvic MRI scan confirmed that this was arising adjacent
to or within the right ovary.
She was transferred to Sheffield and on arrival was breathless
at rest with a resting tachycardia. A presumptive diagnosis of
choriocarcinoma was made and this was later confirmed on review
of the histology from her ruptured ectopic pregnancy, which
initially had not been reported as such. Further staging investiga-
tions including chest imaging and MRI of the brain showed no
evidence of metastatic disease. Serum HCG following transfer was
1.176 106 IU l– 1. She had a WHO risk score of 7 and was
commenced on IV MAE.
Thyroid function tests showed her to be hyperthyroid, with TSH
o0.03mIU l–1, FT4 73 pmol l– 1 and FT3 21.6 pmol l – 1, in keeping
with her symptoms of breathlessness, agitation and resting
tachycardia. She was commenced on carbimazole and propranolol.
After her first cycle of treatment, she developed severe
abdominal pain and swelling. This was associated with a dramatic
fall in serum albumin. Pelvic MRI revealed ascites and a complex
right ovarian mass. A diagnosis of ovarian hyperstimulation
syndrome was made. She was managed conservatively and her
symptoms, signs and serum albumin levels normalised over the
following 10 days with further chemotherapy.
Her TFTs normalised in parallel with the fall in serum HCG
(Table 2; Figure 2). She was slowly weaned off her anti-thyroid
treatment and noted to be biochemically euthyroid at commence-
ment of her third cycle of chemotherapy. She has now completed
chemotherapy, is well with normal serum HCG and remains
clinically and biochemically euthyroid.
Case 3 was a 45-year-old woman who presented 6 weeks after
evacuation of a molar pregnancy detected at her obstetric dating
scan. Histology showed a complete hydatiform mole. Serum HCG
on presentation to our centre was 2.445 106 IU l– 1. Her staging
investigations showed multiple lung metastases. Her WHO risk
score was 8, and she commenced on IV MAE.
Fourteen days after her first cycle of treatment, she presented
acutely breathless. Her serum HCG had fallen by more than half
(942 331 IU l–1), but she was noted to have a suppressed TSH
(o0.03mIU l–1) with normal FT4 (19 pmol l – 1) and FT3
(6.1 pmol l– 1). Her albumin had fallen dramatically (23 g l– 1). She
was noted to have signs and symptoms of acute heart failure and
an echocardiogram showed mild-to-moderate left ventricular
impairment. She was treated symptomatically with diuretics and
commenced on b-blockers. She did not require specific treatment
for her abnormal TFTs, and these normalised with successful
treatment of her GTD. Thyrotoxicosis may have been the cause of
her heart failure, although the differential diagnosis includes
idiopathic post-partum heart failure. Whatever the cause, her
Thyroid function test results by HCG level at presentation
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Figure 1 Frequency of hyperthyroidism by HCG level in patients treated
in Sheffield January 2005 to January 2010. Note: Clinical hyperthyroidism
defined as TSH o0.03mIU l – 1 and signs/symptoms consistent with
hyperthyroidism (tachycardia, tremor and breathlessness) requiring treat-
ment with anti-thyroid drugs (one case with HCG 100 000–500 000 IU l – 1
at presentation and three cases with HCG41mIU l – 1). Biochemical
hyperthyroidism defined as TSH o0.03mIU l – 1 without any clinical signs/
symptoms of hyperthyroidism and not requiring active treatment.
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cardiac function subsequently normalised both clinically and as
evidenced on serial echocardiograms.
After several cycles of chemotherapy, the fall in her HCG levels
plateaued at around 100 IU l–1. She subsequently had a hyster-
ectomy, following which her serum HCG fell to normal. She
remains well with no evidence of active disease, is clinically and
biochemically euthyroid and has normal cardiac function.
Case 4 was a 51-year-old woman who presented to her GP with a
6-month history of lethargy, flushes, abdominal distension and
irregular vaginal bleeding. On examination, she was noted to have
a palpable goitre and a central abdominal mass. Thyroid function
tests showed her to be mildly hyperthyroid with TSH
o0.03mIU l–1, FT3 6.7 pmol l – 1 and FT4 16.7 pmol l– 1.
She was commenced on carbimazole 20mg OD. A computerised
tomography (CT) scan of the abdomen showed a 14 18 cm2
intrauterine mass. While awaiting specialist referral, she presented
to her local accident and emergency department where she
spontaneously delivered a large mass of jelly-like tissue and blood
from the vagina. Histology showed a complete mole. Five days
later, she was transferred to our centre. Serum HCG was
115 942 IU l– 1. Computerised tomography chest showed multiple
small lung metastases. Magnetic resonance imaging of the brain
was normal. Her WHO risk score was 5, putting her into a low-risk
category for which she was commenced on intra-muscular
methotrexate.
At commencement of her chemotherapy, and after 4 weeks
of carbimazole, her TSH was 0.003mIU l– 1, FT4 12.9 pmol l – 1
and FT3 3.6 pmol l – 1. Her TFTs parallelled the fall in her HCG, and
were normal by the start of her second cycle of chemotherapy
(Table 1; Figure 2). Her carbimazole was slowly reduced and
subsequently stopped. Due to an incomplete response to
methotrexate, she required a change of chemotherapy to single
agent intravenous dactinomycin. Her HCG level is now normal,
she is well and clinically and biochemically euthyroid.
DISCUSSION
Subclinical hyperthyroidism is well documented in pregnancy, but
clinical manifestations are uncommon. At the time of peak HCG
levels in normal pregnancy, serum TSH falls and bears a mirror
image to the HCG peak. This fall in TSH suggests that it is HCG
that causes increased secretion of T3 and T4 (Hershman, 2004).
When there are clinical features of thyrotoxicosis, as in some cases
of hyperemesis gravidum, anti-thyroid treatment may be given,
but is rarely required beyond 22 weeks gestation.
Human chorionic gonadotrophin is a glycoprotein composed of
a and b subunits. The a subunit is almost identical to that found in
TSH, luteinising hormone (LH) and follicle-stimulating hormone
(Hershman, 2004). The subunit consists of a 92-amino-acid chain
containing two nitrogen-linked oligosaccharide side chains.
In vitro testing has shown low-affinity cross-reactivity between
these hormones (Vaitukaitis, 1977; Hershman, 2004). The HCG
subunits all target one or more of the G-protein-coupled seven
transmembrane receptors, and have a high degree of homology in
their transmembrane domains (Vassart and Dumont, 1992). The
LH/HCG receptors share 45% homology with the TSH receptor
(Nagayama and Rapoport, 1992; Kohn et al, 1995).
Hyperthyroidism (defined as a suppressed TSH with raised FT3
or FT4) is more common in trophoblastic disease than normal
pregnancy. It is thought that the HCG produced in woman with
GTD has enhanced thyrotrophic activity compared with HCG in
normal pregnancy. This is supported by the observation that
cAMP production is increased more by HCG associated with GTD
when transfected with human TSH-R on Chinese hamster ovary
cells (Kato et al, 2004). When compared with human TSH, studies
using cAMP have identified the potency of purified HCG to be
0.72mU per UHCG (Hershman et al, 1998).
This low potency of HCG for TSH receptors is reflected clinically
when hyperthyroidism is seen in GTN because clinical manifesta-
tion occurs only in the context of very high levels of HCG. Previous
case studies have indicated that serum levels of HCG of
4100 000mIU l–1 are usually needed to produce clinical evidence
of thyrotoxicosis (Odell et al, 1963; Morley et al, 1976; Anderson
et al, 1979; Norman et al, 1981; Soutter et al, 1981).
In our patient cohort, three cases had serum HCG in excess of 1
million at presentation. In case 4, it is likely that her serum HCG
Table 1 WHO prognostic scoring system for GTD
Score
Prognostic factor 0 1 2 4
Maternal age (years) o40 X40
AP Mole Abortion Term
Interval (end of AP to
chemotherapy in months)
o4 4–6 7–13 413
HCG IU l – 1 o103 103–104 104–105 4105
Number of metastases 0 1–4 5–8 48
Site of metastases Lung Spleen, kidney GI tract Brain, liver
Largest tumour mass 3–5 cm 45 cm
Prior chemotherapy Single drug XTwo drugs
Abbreviations: AP¼ antecedent pregnancy; GI¼ gastrointestinal; GTD¼ gestational
trophoblastic disease; HCG¼ human chorionic gonadotrophin; WHO¼World
Health Organisation.
Table 2 Summary of serial HCG and TFT measurements
Day
HCG
(IU l – 1)
TSH
(mIU l– 1)
FT4
(pmol l – 1) Carbimazole
Case 1 0 1 077 249 o0.03 36.3 40mg OD
16 265 008 o0.03 20.7 20mg OD
27 2383 0.14 12.1 10mg OD
38 766 1.2 11.2 Stopped
Case 2 0 791 711 o0.03 73 40mg OD
7 156 420 o0.03 15.2 40mg OD
21 19 986 0.15 16.1 20mg OD
42 333 0.83 12.2 Stop
Case 4 0 115 942 0.03 12.9 20mg OD
2 69 604 0.05 12.2 10mg OD
19 47 966 2.5 6.7 10mg OD
33 4315 1.5 9.8 Stop
Abbreviations: FT4¼ free T4; HCG¼ human chorionic gonadotrophin; OD¼ once
daily; TFT¼ thyroid function test; TSH¼ thyroid-stimulating hormone.
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Figure 2 HCG and TSH trends over time.
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had begun to fall rapidly following spontaneous passage of
the molar tissue, and had the serum HCG been checked when
her hyperthyroidism was diagnosed, the HCG may have been
much higher.
The level of thyroid stimulation is directly proportional to HCG
concentration. Therefore, the severity of clinical hyperthyroidism
also reflects the HCG level. Human chorionic gonadotrophin
thyrotropic activity may also be influenced by metabolism of HCG
molecule; deglycosylation and/or desialylation of HCG may
enhance its thyrotropic properties (Norman et al, 1981).
In the United Kingdom, the co-ordinated and centralised
management of GTN means that patients usually present early
and as such very high levels of HCG are unusual, and thus
hyperthyroidism, especially in a clinically overt form, is rare. This
may not be the case in healthcare systems, which do not enable
early diagnosis.
The largest case series of women with GTD and thyroid disease
comes from Africa. In 27 patients with GTD, more than half
(15 out of 27) were biochemically hyperthyroid (8 choriocarcino-
ma and 7 hydatidiform mole) at presentation. Of these, 60% were
clinically thyrotoxic and one developed acute pulmonary oedema
with associated heart failure. The patients were all euthyroid
once HCG fell to o30 000. It was noted that T4 was raised
invariably, but the T3:T4 ratio was low (0.015þ /0.005) (Norman
et al, 1981).
This seems to be a higher proportion of the patients than
observed in our practice. This could reflect the racial difference
between the cohorts, or differences in health care provision leading
to the women in Africa presenting later in their disease and with
higher HCG levels.
When hyperthyroidism occurs in the context of choriocarcino-
ma, case reports have demonstrated that the biomarkers of
choriocarcinoma and thyroid function parallel the regression
and subsequent relapse of the tumour (Hsieh et al, 2008). This was
also observed in our patients who all responded rapidly to
chemotherapy.
Most patients with symptomatic hyperthyroidism respond
rapidly to treatment. However, there have been a few case reports
of patients with thyroid storm, such as a 17-year-old woman
presenting hyperthyroid with haemodynamic compromise and a
previously undiagnosed molar pregnancy (Moskovitz and Bond,
2009). She required intensive care support, but was treated
successfully with b-blockers and propylthiouracil for her thyroid
disease and underwent a surgical evacuation of her molar
pregnancy, which then required no further treatment. Paradoxi-
cally, severe thyrotoxicosis has also been reported after commen-
cing treatment of GTD. A 53-year-old woman developed profound
cardiovascular instability 1 day after surgical evacuation of a
complete hydatiform mole. She was not known to have pre-
existing thyroid disease, but investigations confirmed thyrotox-
icicosis (Struthmann et al, 2009).
Finally, although there is significant evidence of the cross-over
effects of HCG and TSH, and demonstration of thyrotropic activity
of HCG, it should be noted that concomitant production of
thyrotropin by the tumour cannot be excluded (Cooper et al,
1978). There are no published data regarding this as yet.
CONCLUSIONS
Concomitant biochemical thyroid disease in patients with GTD is
relatively common. Measurement of thyroid function in patients
with persistent GTD is, therefore, important. The development
of hyperthyroidism is largely influenced by the level of HCG
and disease burden. Extremely high levels of HCG are typically
required for the development of clinical hyperthyroidism as the
relative potency of HCG for the TSH receptor is low. As a result,
only a minority are clinically hyperthyroid and require treatment,
although rarely the thyroid stimulation can have potentially life-
threatening consequences. In those requiring treatment, carbima-
zole and b-blockers for symptom relief appear to be effective,
and thyroid function can be expected to normalise rapidly
with treatment of the underlying GTD and the consequent fall in
HCG levels.
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